UNSPSC 51433803: Cilazaprilat

This classification denotes an ace inhibitor with the molecular formula C20H27N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WBL76FH528, chemically known as n-((1s,9s)-1-carboxy-10-oxoperhydropyridazino-(1,2-alpha)(1,2)diazepin-9-yl)-4-phenyl-l-homoalanine but generally known as cilazaprilat, which bears US NIH Compound Identifier 64766. European Medicines Agency schedules Cilazaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06266MIG.

UNSPSC 51433803 Cilazaprilat, a Commodity code, captures prescription medications and related pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and employee benefit plans. State and local buyers under this code source individual medication line items—such as epinephrine, labetalol, adenosine, and diltiazem for Advanced Life Support protocols—as well as broader generic and over-the-counter pharmaceutical inventories through cooperative purchasing arrangements and direct manufacturer relationships. Issuing bodies include municipal fire-rescue departments (Tampa Fire Rescue via the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope reflects both tactical procurement of specific branded or generic medications with firm expiration-date and warranty requirements, and strategic sourcing of multi-source generic pharmaceuticals through authorized wholesalers and direct-to-manufacturer channels.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued Bid No. 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking four specific medication line items for Tampa Fire Rescue with a Small Local Business Enterprise (SLBE) sheltered market designation and a $40,000 estimated contract value. The Texas Health and Human Services Commission issued Request for Information No. HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program intended to establish direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued a Request for Proposal for Generic Multi Source Pharmaceuticals and Over the Counter Products with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with awards effective July 1, 2026, and a contract term of two years with optional extensions.